(1Z,3Z)-1,4-Diazocine | 292-84-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1Z,3Z)-1,4-Diazocine
• 英文别名: 1,4-diazocine
• CAS: 292-84-2
• 化学式: C₆H₆N₂
• 分子量: 106.13
• InChiKey: SBTYJUZFGGEWNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10017497B2

  公开（公告）日：2018-07-10

  The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)化合物或其立体异构体、同分异构体、药学上可接受的盐或其溶液，其中所有变量如本文所定义。这些化合物是可用作药物的 GPR40 G 蛋白偶联受体调节剂。
• Heteroaryl compounds as BTK inhibitors and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10329270B2

  公开（公告）日：2019-06-25

  The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

  本发明涉及可用作 BTK 抑制剂的吡啶、嘧啶、吡嗪和哒嗪化合物及其药学上可接受的组合物。
• Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US10604507B2

  公开（公告）日：2020-03-31

  Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

  本文描述了黑色素皮质素亚型-2 受体（MC2R）调节剂化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗可从调节 MC2R 活性中获益的病症、疾病或紊乱的方法。
• Benzene disulfonamide for the treatment of cancer
  申请人：Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

  公开号：US10913710B2

  公开（公告）日：2021-02-09

  The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6δ and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6δ to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

  本发明涉及新型取代苯二磺酰胺类化合物，以及含有至少一种此类取代苯二磺酰胺类化合物和至少一种药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述取代苯二磺酰胺类药物与 PDE6δ 的芳基结合口袋结合，因此，通过抑制 PDE6δ 与法尼基化 Ras 蛋白的结合，从而抑制细胞中致癌的 Ras 信号传导，可用于预防和治疗癌症。
• Inhibitors of transglutaminases
  申请人：Zedira GmbH

  公开号：US11072634B2

  公开（公告）日：2021-07-27

  The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases.

  本发明涉及作为新型转谷氨酰胺酶抑制剂的通式（I）化合物、生产本发明化合物的方法、含有所述本发明化合物的药物组合物以及它们在预防和治疗与转谷氨酰胺酶有关的疾病方面的用途。